These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 5659736)

  • 1. Growth inhibitory and haematological effects of alkylating agents and attempts at their modification to give greater selectivity of anti-tumour action.
    Elson LA
    Acta Genet Med Gemellol (Roma); 1968 Jan; 17(1):51-9. PubMed ID: 5659736
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutagenic alkylating agents as growth inhibitors and carcinogens.
    Koller PC
    Mutat Res; 1969; 8(1):199-206. PubMed ID: 5796941
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative antitumor effects of peptichemio and other alkylating agents.
    Schmid FA; Banks SE; Stock CC
    Cancer Treat Rep; 1977; 61(3):473-5. PubMed ID: 872145
    [No Abstract]   [Full Text] [Related]  

  • 4. The effects of some steroidal alkylating agents on experimental animal mammary tumor and leukemia systems.
    Wall ME; Abernethy GS; Carroll FI; Taylor DJ
    J Med Chem; 1969 Sep; 12(5):810-8. PubMed ID: 5812193
    [No Abstract]   [Full Text] [Related]  

  • 5. Experimental studies with methylhydrazine derivatives.
    Bollag W
    Acta Genet Med Gemellol (Roma); 1968 Jan; 17(1):158-70. PubMed ID: 5659723
    [No Abstract]   [Full Text] [Related]  

  • 6. Adenosine 3',5'-monophosphate phosphodiesterase activity in experimental animal tumours which are either sensitive or resistant to bifunctional alkylating agents.
    Tisdale MJ; Phillips BJ
    Biochem Pharmacol; 1975 Jan; 24(2):205-10. PubMed ID: 163093
    [No Abstract]   [Full Text] [Related]  

  • 7. Alkylating analogues of the tumour inhibitor 5-aziridino-2,4-dinitrobenzamide.
    Tisdale MJ
    Chem Biol Interact; 1971 Apr; 3(2):95-107. PubMed ID: 5156644
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies on the selectivity of antitumor agents.
    Garattini S; Guaitani A; Nanni E; Palma V
    Cancer Res; 1967 Dec; 27(12 Pt 2):1309-437. PubMed ID: 4295303
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative antitumour and haematological effects of some bifunctional alkylating agents containing mixed functional groups.
    Tisdale MJ; Elson LA; Ross WC
    Eur J Cancer (1965); 1973 Feb; 9(2):89-97. PubMed ID: 4717491
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies.
    Hall AG; Tilby MJ
    Blood Rev; 1992 Sep; 6(3):163-73. PubMed ID: 1422285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of chemical agents against the plasma cell tumor LPC-1 in mice.
    Abraham D; Carbone PP; Venditti JM; Kline I; Goldin A
    Biochem Pharmacol; 1967 Apr; 16(4):665-73. PubMed ID: 6033787
    [No Abstract]   [Full Text] [Related]  

  • 12. Antitumor agents. 31. Helenalin sym-dimethylethylenediamine reaction products and related derivatives.
    Lee KH; Ibuka T; Mar EC; Hall IH
    J Med Chem; 1978 Jul; 21(7):698-701. PubMed ID: 671468
    [No Abstract]   [Full Text] [Related]  

  • 13. Modulation of the toxicity and antitumour activity of alkylating drugs by steroids.
    Shepherd R; Harrap KR
    Br J Cancer; 1982 Mar; 45(3):413-20. PubMed ID: 7073935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2,4-dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256.
    Cobb LM; Connors TA; Elson LA; Khan AH; Mitchley BC; Ross WC; Whisson ME
    Biochem Pharmacol; 1969 Jun; 18(6):1519-27. PubMed ID: 4307990
    [No Abstract]   [Full Text] [Related]  

  • 15. Recent advances in chemotherapy of lymphoma.
    Lenhard RE; Owens AH
    Johns Hopkins Med J; 1967 Aug; 121(2):136-40. PubMed ID: 5340335
    [No Abstract]   [Full Text] [Related]  

  • 16. Reduction of the toxicity of radiomimetic alkylating agents in rats by thiol pretreatment. V. The effect of thiol pretreatment on the anti-tumour action of Merophan.
    Connors TA; Jenney A; Whisson ME
    Biochem Pharmacol; 1965 Nov; 14(11):1681-3. PubMed ID: 5867521
    [No Abstract]   [Full Text] [Related]  

  • 17. Spectrum and selectivity of antitumor action of phenesterin.
    Degteva SA
    Fed Proc Transl Suppl; 1965; 24(6):1111-2. PubMed ID: 5215182
    [No Abstract]   [Full Text] [Related]  

  • 18. [A method of primary selection of antitumor agents].
    Karaivanova MKh
    Vopr Onkol; 1971; 17(2):62-6. PubMed ID: 5567711
    [No Abstract]   [Full Text] [Related]  

  • 19. The clinical trial of an alkylating agent with a short half-life designed for intra-arterial chemotherapy.
    Meyza J; Cobb LM
    Cancer; 1971 Feb; 27(2):369-73. PubMed ID: 5100399
    [No Abstract]   [Full Text] [Related]  

  • 20. Synthesis, chemistry, and preliminary pharmacology of arsenical nitrogen mustards and structurally related nonalkylating arsenicals.
    Bardos TJ; Datta-Gupta N; Hebborn P
    J Med Chem; 1966 Mar; 9(2):221-7. PubMed ID: 5911802
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.